Navigation Links
Escalon(R) Subsidiary Sonomed Introduces New PacScan(TM) Plus A-Scan and Pachymeter
Date:10/24/2009

WAYNE, Pa., Oct. 23 /PRNewswire-FirstCall/ -- Escalon Medical Corp. (Nasdaq: ESMC) today announced its Sonomed, Inc. subsidiary's introduction of the new PacScan(TM) Plus, an A-Scan with optional pachymeter.

"The PacScan(TM) Plus is the latest generation of our combination instruments, and incorporates several advancements, including provision of three post-refractive IOL formulas," Barry Durante, President, commented. "The data storage and transfer capabilities, built-in printer, and probe storage compartment make the PacScan(TM) Plus a truly portable full-function system."

Sonomed will be demonstrating the PacScan(TM) Plus at the upcoming AAO meeting in San Francisco, CA October 24-27, 2009.

The PacScan(TM) Plus features a large high-contrast color LCD, five programmable user profiles, and nine IOL formulas, including three post-refractive. Immersion and direct contact scanning is provided with cataract, dense cataract, aphakic, pseudophakic and 4-gate manual modes. The PacScan(TM) Plus has a USB port for EMR archiving and a SD disk port for patient data storage, as well as a built-in thermal printer, built-in probe holders, probe storage compartment, and individual probe connectors.

Founded in 1987, the Company (www.escalonmed.com) develops markets and distributes ophthalmic diagnostic, surgical and pharmaceutical products as well as vascular access devices. Drew Scientific, which operates as a separate business unit, provides instrumentation and consumables for the diagnosis and monitoring of medical disorders in the areas of diabetes, cardiovascular diseases and hematology, as well as veterinary hematology and blood chemistry. The Company seeks to utilize strategic partnerships to help finance its development programs and is also seeking acquisitions to further diversify its product line to achieve critical mass in sales and take better advantage of the Company 's distribution capabilities, although such partnerships or acquisitions may not occur. The Company has headquarters in Wayne, Pennsylvania and operations in Long Island, New York, New Berlin, Wisconsin, Lawrence, Massachusetts, Dallas, Texas, Waterbury, Connecticut, Miami, Florida, Barrow-in-Furness, U.K. and Le Rheu, France.

Note: This press release contains statements that are considered forward-looking under the Private Securities Litigation Reform Act of 1995, including statements about the Company's future prospects. These statements are based on the Company's current expectations and are subject to a number of uncertainties and risks, and actual results may differ materially. The uncertainties and risks include whether the Company is able to:

  • implement its growth and marketing strategies, improve upon the operations of the Company business units, including the ability to make acquisitions and the integration of any acquisitions it may undertake, if any, of which there can be no assurance,
  • implement cost reductions,
  • generate cash,
  • identify, finance and enter into business relationships and acquisitions.

Other factors include uncertainties and risks related to:

  • new product development, commercialization, manufacturing and market acceptance of new products,
  • marketing acceptance of existing products in new markets,
  • research and development activities, including failure to demonstrate clinical efficacy,
  • delays by regulatory authorities, scientific and technical advances by the Company or third parties,
  • introduction of competitive products,
  • ability to reduce staffing and other costs and retain benefit of prior reductions,
  • third party reimbursement and physician training, and
  • general economic conditions.

Further information about these and other relevant risks and uncertainties may be found in the Company's report on Form 10- K for year ended June 30, 2009, and its other filings with the Securities and Exchange Commission, all of which are available from the Securities and Exchange Commission as well as other sources.

SOURCE Escalon Medical Corp.


'/>"/>
SOURCE Escalon Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Escalon(R) Reports Fourth Quarter and Fiscal 2009 Results
2. Escalon(R) Announces Going Concern Qualification
3. Nyer Medical Group, Inc., Announces Agreements to Sell Certain Eaton Apothecary Assets to Walgreens and Sell Operating Subsidiarys Stock to Investors
4. Cantel Medicals Crosstex Subsidiary Launches New Specially Treated Face Mask Effective Against H1N1 Influenza
5. Subsidiary of Nova Biomedical Completes Acquisition of Assets of CCS Medicals Subsidiary, Sanvita, Inc.
6. New Places and People - Truphatek opens USA subsidiary
7. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
8. Cantel Medical Corp.s Crosstex Subsidiary Addresses School MRSA Concerns With SaniTyze(TM) Brand Hand Sanitizer and Sanitex(R) Surface Disinfecting Line of Products
9. Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies
10. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
11. IRIDEX Introduces IQ 532 Dual Port Green Laser System at the American Academy of Ophthalmology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)...  Alopexx Oncology, LLC announced data from a Phase ... (immunocytokine) composed of interleukin-2 and a CD20-targeting monoclonal antibody. ... cells as Rituxan and maintains the activities of both ... in tumor targeting, engagement of the immune system, and ... the study (abstract #95954) were presented at the 58 ...
(Date:12/6/2016)... Dec. 6, 2016 Homozygous Familial ... Summary Global Markets Direct,s latest ... Familial Hypercholesterolemia (HoFH) – Pipeline Review, H2 ... Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) pipeline landscape. ... disorder which is caused due to mutation ...
(Date:12/6/2016)... 6, 2016   AlloSource , one of ... skin and soft-tissue allografts for use in surgical ... Manager, for being named to the Board of ... Award by the Commerce Department,s National Institute of ... to process excellence. The Baldrige Award is the ...
Breaking Medicine Technology:
(Date:12/7/2016)... (PRWEB) , ... December 07, ... ... Technologies, announced its newest portable bioelectronic medicine device WellnessPro Plus for consumers ... Plus substantially enhances the WellnessPro platform by expanding the treatment modalities available ...
(Date:12/7/2016)... ... ... “Tomorrow Trump Goes To Washington”: a brief but engaging illustration depicting the ... “Tomorrow Trump Goes To Washington” is the creation of published author, Nancy Engestrom, a ... Nancy attributes her patriotic nature to her WWII veteran father. She says, “I ...
(Date:12/7/2016)... NORFOLK, Va. (Dec. 3, 2016) , ... (PRWEB) ... ... the nation’s only patient advocacy nonprofit for individuals impacted by cerebral cavernous angiomas, ... work in New Mexico with a patient engagement program. New Mexico has more ...
(Date:12/7/2016)... ... 2016 , ... NuevaCare, a leading home care agency based in San Mateo ... pages as part of its ambitious website relaunch. As Bay Area clients scramble to ... agencies serving their city. The new site has several key city-specific pages to address ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... collaborate in developing a vaccine against the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). ... available in South Korea for emergency deployment in the event of a future ...
Breaking Medicine News(10 mins):